- Raised $30M funding round led by Arix Bioscience, Dec 2017
- Raised $23M funding round led by SR One, Jul 2014
- Raised $6.5M grant, Apr 2002
About
Atox Bio is a late-stage biotechnology company that develops novel immunomodulators for critically ill patients. The companys lead product, Reltecimod, is initially being developed to treat necrotizing soft-tissue infection (NSTI), a rare, life-threatening infection for which no therapy currently exists. Atox Bio recently completed enrollment of the Reltecimod clinical composite endpoint study in necrotizing soft tissue infections study (ACCUTE), a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI. Results of the study are expected to be presented at a medical meeting in the first half of 2020. The companys previous phase 2 study of Reltecimod in NSTI demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple endpoints. Reltecimod was granted fast track and orphan drug designations for NSTI by the FDA and orphan medicinal product designation for NSTI by the European Commission. Development of Reltecimod is supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA).
Funding history · 5 rounds · $64.8M total
Q&A
- What is Atox Bio's primary focus?
- Atox Bio is a late-stage biotechnology company that develops novel immunomodulators for critically ill patients, with a lead product, Reltecimod, for necrotizing soft-tissue infection (NSTI).
- What is the status of Atox Bio's operations?
- Atox Bio is currently inactive and ceased to operate in May 2022.
- When was Atox Bio founded?
- Atox Bio was founded in May 2003.
- What was Atox Bio's most recent funding round?
- In December 2017, Atox Bio raised $30,000,000 in a funding round led by.
- Which organizations supported the development of Reltecimod?
- The development of Reltecimod is supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA).
- Has Reltecimod received any special designations?
- Reltecimod was granted fast track and orphan drug designations for NSTI by the FDA and orphan medicinal product designation for NSTI by the European Commission.
- Who are the co-founders of Atox Bio?
- The co-founders of Atox Bio are Gila Arad and Prof. Raymond Kaempfer.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | atoxbio.com |
|---|---|
| linkedin.com/company/1196215 |
Identifiers & details
| Founded | 2003-5 |
|---|---|
| Employees (exact) | 29 |
| Offices | Durham |
| Status reason | Non Active, May 2022 ceased to operate |